公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2014 | A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma | Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; CHIUN HSU ; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y. | Clinical Cancer Research | 95 | 85 | |
2020 | Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial | Xu J.; Xu R.-H.; Qin S.; Pan H.; Bai Y.; Chi Y.; Wang L.; Bi F.; Cheng Y.; Liu T.; Ma D.; Shen L.; Ba Y.; Liang J.; Wang X.; Yau T.C.C.; Ma B.B.; KUN-HUEI YEH ; Lin J.-K.; Kappeler C.; Shapiro J.; Kalmus J.; Li J. | Journal of Gastroenterology and Hepatology (Australia) | 7 | 5 | |
2015 | Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial | Li J.; Qin S.; Xu R.; Yau T.C.C.; Ma B.; Pan H.; Xu J.; Bai Y.; Chi Y.; Wang L.; KUN-HUEI YEH ; Bi F.; Cheng Y.; Le A.T.; Lin J.-K.; Liu T.; Ma D.; Kappeler C.; Kalmus J.; Kim T.W. | The Lancet Oncology | 597 | 536 |